Cancer Metabolism: Strategic Diversion from Targeting Cancer Drivers to Targeting Cancer Suppliers.
10.4062/biomolther.2015.013
- Author:
Soo Youl KIM
1
Author Information
1. Cancer Cell and Molecular Biology Branch, Division of Cancer Biology, Research Institute, National Cancer Center, Goyang 410-769, Republic of Korea. kimsooyoul@gmail.com
- Publication Type:Review
- Keywords:
Cancer;
Metabolism;
Cancer therapy
- MeSH:
Autophagy;
Biology;
Glycolysis;
Metabolism*;
Molecular Biology;
Respiration;
Imatinib Mesylate
- From:Biomolecules & Therapeutics
2015;23(2):99-109
- CountryRepublic of Korea
- Language:English
-
Abstract:
Drug development groups are close to discovering another pot of gold-a therapeutic target-similar to the success of imatinib (Gleevec) in the field of cancer biology. Modern molecular biology has improved cancer therapy through the identification of more pharmaceutically viable targets, and yet major problems and risks associated with late-phase cancer therapy remain. Presently, a growing number of reports have initiated a discussion about the benefits of metabolic regulation in cancers. The Warburg effect, a great discovery approximately 70 years ago, addresses the "universality" of cancer characteristics. For instance, most cancer cells prefer aerobic glycolysis instead of mitochondrial respiration. Recently, cancer metabolism has been explained not only by metabolites but also through modern molecular and chemical biological techniques. Scientists are seeking context-dependent universality among cancer types according to metabolic and enzymatic pathway signatures. This review presents current cancer metabolism studies and discusses future directions in cancer therapy targeting bio-energetics, bio-anabolism, and autophagy, emphasizing the important contribution of cancer metabolism in cancer therapy.
